A new scientific publication involving buserelin was released on October 15, 2026. The paper, titled "Ovulation Timing After Recombinant Human Chorionic Gonadotropin, Gonadorelin, or Buserelin Under Estrus-Triggered and Fixed-Time Treatment Protocols for Artificial Insemination in Sows," appeared in the journal Animals, an open access journal from MDPI.
The publication compares buserelin alongside recombinant human chorionic gonadotropin and gonadorelin within the context of estrus-triggered and fixed-time treatment protocols used for artificial insemination in sows. This entry reflects the existence and title of the publication as listed in the source record.
No findings, outcomes, or efficacy data from this study are detailed here. Readers interested in the full scope of the research, including its methodology and any reported results, are encouraged to consult the publication directly through the listed source.
Buserelin remains an approved compound. This brief does not characterize the study's conclusions or imply any particular result regarding ovulation timing or insemination success. For more background on buserelin, including its general profile and regulatory history, see the compound overview.